InflaRx N.V.
Open
$2.08
Prev. Close
$2.08
High
$2.08
Low
$2.07
Market Snapshot
$134.14M
-2.5
-0.86
$183.14K
65
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
emptyResult
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Recently from Cashu
InflaRx N.V. Advances Drug Pipeline in Autoimmune Disease amid Biotech Industry Changes
InflaRx N.V. Leverages Drug Development Pipeline Amidst Industry Shifts InflaRx N.V. stands at a critical junction in the biotechnology sector, focusing on the advancement of its innovative drug devel…
InflaRx N.V. Pursues Innovative IL-1α Inhibition for Treating Severe Inflammatory Diseases
### InflaRx N.V. Targets IL-1α Pathway in Novel Therapeutic Approach InflaRx N.V. focuses on the innovative treatment of severe inflammatory diseases by developing its proprietary biological drugs aim…
InflaRx N.V. Prioritizes Izicopan Development While Cutting Costs and Streamlining Operations
InflaRx N.V. Prioritizes Key Drug Development Amid Cost-Cutting Measures InflaRx N.V. announces a strategic initiative aimed at reducing costs and streamlining operations to extend its financial runwa…
InflaRx N.V. Focuses on Izicopan During Financial Restructuring Efforts
InflaRx N.V. Prioritizes Izicopan Amid Financial Restructuring InflaRx N.V. announces a strategic initiative aimed at reducing costs and streamlining operations to extend its financial runway. In a de…